How to enhance Vitality and the latest information about Regenerative Medicine, Stem Cells, Platelet Rich Plasma and Sports Medicine
Wednesday, October 03, 2007
Horse Treated Acutely with Platelet Rich Plasma for Tendon Injury
http://www.standardbredcanada.ca/news/iss1007/wearableart1002.html
For more information about PRP, please visit: Total Tendon.com and/or ApexPRP.com
Tuesday, October 02, 2007
FDA Approves PRP for Wound Healing
http://biz.yahoo.com/ap/070920/cytomedix_autologel_fda.html?.v=1
ApexPRP.com
Total Tendon.com
Sunday, July 29, 2007
Everts Article on Structural Features of PRP

Everts et al (European Surgical Research: 2007) recently published their findings of the structure of platelet rich plasma. Their work is important because it will lead to a better understanding of how and when to use PRP. Further work about exactly how growth factors are released from both platelets and white blood cells is clearly needed. This important paper leads the way.The picture above is from Evert's fine paper. The top picture is a platelet gel aggregate before the growth factors have been released. The bottom picture clearly shows the empty alpha granules indicating release of growth factors.
For more PRP information, visit: ApexPRP.com
Wednesday, July 04, 2007
Using Platelet Rich Plasma for a LASIK complication
AM from ApexPRP
Treatment of ocular surface syndrome after LASIK with autologous platelet-rich plasma.
PURPOSE: To ascertain the usefulness of platelet-rich plasma in the treatment of patients suffering from symptomatic ocular surface syndrome following LASIK. METHODS: Twenty-six eyes (9 women and 4 men) affected by symptomatic ocular surface syndrome were treated with topical eye drops of autologous platelet-rich plasma and results were reported at 4 weeks. Topical platelet-rich plasma was prepared from total blood and enriched in platelets by centrifugation. RESULTS: Eighty-five percent of patients experienced significant improvement of symptoms; best spectacle-corrected visual acuity increased 1 to 2 lines in 54%; fluorescein staining analysis showed a 69% full fluorescein disappearance; and tear break-up time increased > 2 seconds in 46%. Only one patient developed intolerance to platelet-rich plasma after 4 weeks. CONCLUSIONS: Autologous platelet-rich plasma was effective in the treatment of patients with ocular surface syndrome following LASIK, with symptoms generally relieved and a positive effect on punctate keratitis. Refract Surg. 2007 Jun;23(6):617-9.
Monday, June 25, 2007
PRP and Muscle Tears
This research is rapidly evolving so watch this blog for updates.
ApexPRP.com
Tuesday, June 05, 2007
Platelet Rich Plasma CBS News
CBS Evening News Story
For more information about PRP, please visit: ApexPRP.com
Sunday, June 03, 2007
Achilles Tendon Repair with PRP

Published data supports the use of platelet rich plasma to augment Achilles Tendon repairs. In the picture above, PRP is injected into the sheath around the tendon just prior to skin closure.
Wednesday, May 23, 2007
PRP Improves Wound Healing
This is clear evidence that PRP enhances wound healing. In orthopedics and a variety of other specialties, PRP should be strongly considered when doing procedures that have a potentially high wound complication rate such as achilles tendon repair.
The rate of platelet rich plasma publications has also risen dramatically. This indicates more interest in PRP and now more evidence to support its use.
For more information about PRP please visit: ApexPRP.com
Sunday, May 13, 2007
Platelet Rich Plasma inhibits Macrophages
For more PRP information, visit ApexPRP.com
Cellular effects of platelet rich plasma: a study on HL-60 macrophage-like cells.
Woodall J Jr, Tucci M, Mishra A, Benghuzzi H.
Biomed Sci Instrum. 2007;43:266-71.
Healing injured tissue in the body is a complex process which consists of four distinct phases: hemostasis, inflammation, proliferation, and remodeling. Each of these phases is coordinated by growth factor release and cell to cell interactions. Platelet rich plasma (PRP) is a fraction of plasma that has been isolated and used to enhance regeneration in bone and soft tissues. The healing potential of PRP has been attributed to the release of multiple growth factors from the highly concentrated platelets. While there is strong evidence of the pro-stimulatory effect on the cellular proliferation phase of healing, there is little evidence of the effects of PRP on the inflammatory phase of healing. In this study we investigate the effect that PRP has on macrophage cells in culture and the implications this has on the healing process. We investigate specifically the effects of the separate cellular components of PRP, as a whole and individually, on cell proliferation in human macrophage cells in culture. In contrast to the pro-stimulatory effect that PRP has on cells such as osteoblasts, fibroblasts, and tendon cells; our results show a suppression of macrophages by PRP as early as 24 hours after treatment. This suppression was statistically significant (p=0.002) and continued to be significant for the duration of the study. The cell viability results of PRP compared to platelet poor plasma (PPP) and individual components of PRP showed that PRP resulted in a steady increase in viability following the initial insult to the macrophage cells, while the viability of other treatment groups seemed to plateau.
Monday, May 07, 2007
Platelet Rich Plasma and pH
ApexPRP
Platelets. 2007 Mar;18(2):113-8.
Variation of pH in lysed platelet concentrates influence proliferation and alkaline phosphatase activity in human osteoblast-like cells.
Wahlstrom O, Linder C, Kalen A, Magnusson P.
Faculty of Health Sciences, Division of Orthopaedics, Department of Neuroscience and Locomotion, SE-581 85 Linkoping, Sweden. olawa@inr.liu.se
Activated platelets release a multifaceted blend of growth factors that has stimulatory effects on mesenchymal cells, both in vitro and in vivo, which imply beneficial effects on wound repair and tissue regeneration. Previous studies on fibroblast cultures have revealed that more potent growth factors, with respect to cell proliferation, are released in acidic preparations of lysed platelet concentrates in comparison with neutral and alkaline preparations. The current study was intended to investigate the influence of pH on lysed platelet concentrates with respect to release of growth factors, cell proliferation and alkaline phosphatase (ALP) activity in human osteoblast-like cells (hFOB 1.19). Cell proliferation was assessed with the MTT kit, ALP activity by conventional enzymatic reaction kinetics and growth factors platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-beta) by enzyme-linked immunosorbent assays. Osteoblast-like cells were stimulated with lysed platelet concentrates preincubated at pH 4.4, 5.4, 7.4, and 7.6. A 3-13-fold increase of cell proliferation was found in comparison with controls and the most evident increase was observed with platelets activated at pH 5.4. The highest ALP activity was observed in preparations at pH 7.6. Platelets incubated in an acidic environment (pH 5.4) induced a higher proliferation compared with preincubation at neutral or alkaline pH and the level of PDGF was also found to be higher in acidic preincubations. The level of TGF-beta was, in contrast, lowest at pH 4.4. We suggest, based on these experimental findings, that acidic milieu influence platelets to release growth factors more potent to stimulate osteoblast proliferation than neutral and alkaline platelet preparations. Lysed platelet concentrates prepared at an alkaline pH might release additional components with stimulating effects resulting in other features than cell proliferation. This is the first report, to our knowledge, about a pH dependent stimulatory effect of lysed platelet concentrates on human osteoblast-like cell proliferation. Lysed platelet concentrates, preincubated in acidic or alkaline buffers, may benefit fracture healing, implant fixation and might also be advantageous in the treatment of wounds with platelet constituents; however, this has to be investigated in extended experimental and clinical settings.